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NeonatesBackground: In Guinea-Bissau we conducted a randomized trial of OPV0 versus No OPV0 to test the effect
of not receiving OPV0 on infant mortality and morbidity. In two subgroups of participants, 6-week-old
children and 6-month-old children, we investigated the effect of OPV0 on neutralizing antibodies against
poliovirus type 1 and 3.
Design: A subgroup of infants randomized to receive OPV0 or No OPV0 in addition to the usual childhood
vaccines were visited at home at 6 weeks or 6 months of age, and a blood sample was collected from the
child and the mother.
Setting: Urban Guinea-Bissau.
Main outcome: Geometric mean titers (GMT) of neutralizing antibodies and seropositivity (titerP 1:8)
for poliovirus type 1 and 3.
Results: OPV0 did not affect the overall seropositivity at 6 weeks or 6 months of age for either polio 1 or 3.
In 6-week-old infants, not receiving OPV0 was associated with signiﬁcantly lower GMT for polio 1 and 3
(GMT ratio = 0.52 (95% CI = 0.33–0.79) for polio 1; 0.44 (0.28–0.70) for polio 3), the effect being signiﬁcant
in its own right in boys and in children whose mothers had low antibody levels. In contrast, in 6-month-
old infants, not receiving OPV0 was associated with signiﬁcantly higher GMT for polio 1 (GMT ratio = 2.10
(1.32–3.35)). This was signiﬁcant in its own right in boys and in children of mothers with high antibody
levels.
Conclusions: OPV0 may contribute to early polio protection, particularly in children of mothers with low
antibody levels. However, OPV0 did not contribute to overall polio immunity after subsequent doses of
OPV were given, and was associated with signiﬁcantly lower antibody titers in children of mothers with
high antibody levels. However, it did not negatively affect the proportion of seropositive children.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Oral polio vaccine (OPV) at birth was introduced to ensure early
protection against polio and to increase coverage [1,2]. Studies
have shown that OPV at birth (OPV0) increases antibody titers be-
tween birth and 6 weeks of age compared with No OPV0, but notafter 4 months of age when the children have received three addi-
tional OPV doses (OPV1–3) [2,3]. The effect of OPV0 on overall
child mortality and on the immune response to other vaccines
was never studied.
In 2004 in Guinea-Bissau, two randomized trials were ongoing,
testing the effect of neonatal vitamin A supplementation in nor-
mal-birth-weight children and the effect of BCG at birth to low-
birth-weight children, respectively [4,5]. That year the country
experienced periods when OPV was in short supply. Surprisingly,
not receiving OPV0 was associated with signiﬁcantly lower mortal-
ity in boys while it made no difference for girls [6]. At age 6 weeks,
the in vivo and in vitro immune responses to BCG vaccine were
34 A.S. Hansen et al. / Trials in Vaccinology 3 (2014) 33–39reduced in infants who had received OPV0 with BCG compared to
those who had only received BCG [7]. These effects were found in
both sexes.
If OPV0 has negative effects onmalemortality or on the immune
response to BCG vaccine, it is essential to reassess the importance of
OPV0 for polio immunity. Today, most pregnant women have been
vaccinated against polio and have not experienced natural polio
infection.Hence, they are likely to transfer lower levels of antibodies
to their offspring which may increase the immunogenicity of OPV0
[8,9]. Also, the BCG vaccine administered simultaneously with
OPV0 may inﬂuence the immune response to OPV [10].
Intestinal immunity to poliomyelitis correlates with serum
antibody titer [11]. In the present study we assessed the effect of
OPV0 provided with BCG at birth on polio antibody titers at
6 weeks of age and at 6 months of age.Materials and methods
Setting
The study was conducted at the Bandim Health Project (BHP),
Guinea-Bissau, which covers an urban area with a health and
demographic surveillance system (HDSS) monitoring around
102,000 individuals. The recommended vaccination schedule is
BCG and OPV0 at birth, three doses of pentavalent vaccine and
OPV (OPV1–3) at 6, 10 and 14 weeks of age, and measles vaccine
and yellow fever vaccine at 9 months of age.
Main OPV0 trial
Healthy normal-birth-weight children (P2.5 kg) less than
1 month old were eligible for the main randomized trial. Mothers
giving birth at the national hospital or bringing their child for
vaccination at one of the three local health centers were invited
to participate before their child received BCG and OPV. The ran-
domization to OPV0 or No OPV0 was stratiﬁed by sex. All children
received BCG.
The present subgroup study
The study took place between August 18 and November 27
2009 and again from February 8 to April 22 2010. We bled two co-
horts of children: A cohort of 6-week-old children and a cohort of
6-month-old children. Eligible were children enrolled in the main
trial within the ﬁrst week of life and who had not been included in
a concurrent study examining in vitro cytokine responses. Children
who had received a routine OPV1 before the recommended age of
6 weeks, and thus before the 6-week-sample, were not included in
the 6-week cohort, to assure a pure comparison between No OPV0
and OPV0. Due to limited resources we were unable to recruit 105
of the eligible 6 week children and 23% of the eligible 6-month-
old-children (Fig. 1). At enrolment the mother was bled as well,
to assess maternal antibodies against polio type 1 and 3.
OPV campaigns
We planned to enroll children until May 2010, but from March
6–9 and again from April 24–27 2010, national polio immunization
campaigns provided monovalent OPV directed against polio type 1
for all children aged 0–5 years. Since we aimed for a pure compar-
ison between No OPV0 and OPV0 in 6-week-old children, we
stopped including 6-week-old children on March 4 2010, before
the ﬁrst campaign. The enrolment of 6-month-old children contin-
ued, as the aim in this group was to study the long-term impact of
No OPV0 in children who had received additional OPV. However,we stopped just before the second round as we had almost reached
the sample size and were aware that OPV provided in the
campaigns could dilute any effect. Hence, a subgroup of the
6-month-old children (N = 83) had received one dose of monova-
lent OPV during the campaign (cOPV). Information on cOPV was
obtained on two occasions. First, immediately after the campaign
BHP assistants visited all children in the study area and asked
whether the child had received cOPV. If so, it was noted on the
child’s vaccination card. Second, at the time of the bleeding, the
mother was asked once more, and the vaccination card was
checked for consistency.
Sample size
We aimed to obtain 300 samples from children at the age of
6 weeks and 300 samples from children aged 6 months. However,
we were not able to reach that target for 6-week old children
due to the national polio immunization campaigns.
Laboratory methods
Capillary blood samples were collected in EDTA coated micro-
tainers. Polio 1 and polio 3 neutralizing antibody titration assays
were performed in duplicate using the standard polio neutraliza-
tion assay described in the EPI manual, World Health Organization
(WHO) 1997 [12], at a starting dilution of 1:8 and the assays were
incubated for 5 days. The assays were read by three different oper-
ators. An internal standard, cell quality control and virus control
were included for analysis of each batch of sample plasma. The
internal standard was calibrated against the WHO international
reference preparation. The geometric mean titer for the internal
standard for polio type 1 and polio type 3 was 1:360 and 1:428,
respectively, with a potency established by calibration of 21 IU
for type 1 neutralizing antibodies and 7 IU for type 3 neutralizing
antibodies, thus the sensitivity of the polio 1- and polio 3 assays
were 58 and 16 mIU respectively. Dilutions of P1:8 were consid-
ered seropositive. If there was insufﬁcient plasma, we prioritized
the measurement of polio 1 antibody levels.
Statistical methods
Statistical analyses were carried out using STATA 10.1. P-values
<0.05 were considered statistically signiﬁcant. For background
characteristics, categorical variables were compared using the v2
test and continuous variables were compared by Student’s t-test.
Mean and standard deviation (SD) were presented for continuous
variables. For age which was not normally distributed, the median
and the interquartile range (25–75 centile) were presented.
Seropositivity rates were calculated for each serotype. Seropos-
itivity prevalence ratios were calculated using Poisson regression
with robust variance estimates [13]. Geometric mean titers
(GMT) were calculated for seropositive children (titerP 1:8). To
calculate the ratio between the GMT in the No OPV0 group and
the GMT in the OPV0 group (the GMT ratio) a linear regression
was conducted with the log-transformed titers as outcome and
the randomization group as a covariate. The GMT ratio was
obtained as anti-log (exp) of the coefﬁcient for the group differ-
ence. Hence, a GMT ratio of 2 would mean that the GMT in the
No OPV0 group was twofold higher than the GMT in the OPV0
group. GMT > 1:512 were set to 1:1024. Tobit regression was used
to account for this right-censoring.
Both crude and adjusted analyses were conducted. The adjusted
analyses included: sex, age at enrolment (0–1 days or 2–7 days),
and season of enrolment (rainy season (June–November) or dry
season (December–May)). These factors were included since
randomization was stratiﬁed by sex, age is generally an import
Fig. 1. Flowcharts.
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vaccine responses. Due to differences in antibody titer measure-
ments, analyses were adjusted for the person conducting the assay
(operator 1, 2 or 3).
Ethical considerations
There have been no polio cases in Guinea-Bissau for the past
10 years. The protocol was approved by the Guinean Ministry of
Health’s Research Coordination Committee, and the Danish Central
Ethics Committee gave its consultative approval. The trial was reg-
istered at www.clinicaltrials.gov (NCT00710983).
Results
Study populations
At 6 weeks of age, of 262 children eligible for inclusion, 189
children were bled (Fig. 1). There were no signiﬁcant differences
in any background characteristics between those bled at 6 weeks
and the remaining eligible children (data not shown) or between
the two randomization groups (Table 1).
At 6 months of age, of 544 children eligible for inclusion, 275
children were bled (Fig. 1). There were signiﬁcant differences in
the anthropometric measures at enrolment into the main trial
between the children bled at 6 months and the remaining eligible
children. Bled children tended to be larger (p = 0.005 for weight;
p = 0.01 for length; p = 0.02 for MUAC) and more of their mothershad attended school (p = 0.006). Among included children, signiﬁ-
cantly more children in the No OPV0 group received cOPV
(p = 0.05, Table 1).
Polio antibody levels in children at 6 weeks and 6 months of age
There were no signiﬁcant differences in the prevalence of sero-
positivity to polio 1 and 3 between the No OPV0 and OPV0 groups
at either 6 weeks or 6 months of age (Table 2). However, the prev-
alence was generally higher in the OPV0 group at both time points.
At 6 weeks, the GMT was signiﬁcantly lower for No OPV0 com-
pared to OPV0 for polio 1 (GMT ratio = 0.51 (95% CI: 0.33–0.79) and
polio 3 (GMT ratio = 0.44 (0.28–0.70). These effects were signiﬁ-
cant in their own right for boys, but did not differ signiﬁcantly from
the effect in girls (test for interaction between OPV0 and sex for
polio 1 (p = 0.10) and for polio 3 (p = 0.21)).
At 6 months, the results were opposite for polio 1; the polio 1
GMT was twofold higher for No OPV0 compared with OPV0
(GMT ratio = 2.10 (1.32–3.35). There was no difference with re-
gard to polio 3 GMT (GMT ratio = 1.00 (0.70–1.42). The increased
polio 1 GMT in the No OPV0 group was also seen in the sub-
group of children who were vaccinated according to recommen-
dations and had received all three doses of OPV1–3, but not
cOPV1 (Table 3).
The effect of No OPV0 was examined according to mothers’
antibody levels being below or above the median (Table 4). At
6 weeks, the GMTs were signiﬁcantly lower in No OPV0 compared
to OPV0 among children with maternal antibody levels below the
Table 2
Comparison of polio neutralizing antibody titers at 6 weeks and 6 months of age in the two randomization group.
6 weeks 6 months
No OPV0 OPV0 Seropositivity ratio GMT ratio No OPV0 OPV0 Seropositivity ratio GMT ratio
Polio 1 Overall N = 85 N = 88 N = 123 N = 149
Seropositive 84% 88% 0.95 (0.84–1.08) 89% 94% 0.94 (0.87–1.02)
GMT 30 58 0.51 (0.33–0.79) 851 405 2.10 (1.32–3.35)
Boys N = 48 N = 46 N = 69 N = 80
Seropositive 85% 89% 0.96 (0.82–1.12) 94% 96% 0.98 (0.91–1.05)
GMT 31 86 0.36 (0.20–0.64) 852 357 2.39 (1.29–4.40)
Girls N = 37 N = 42 N = 54 N = 69
Seropositive 81% 86% 0.95 (0.78–1.15) 81% 91% 0.89 (0.77–1.03)
GMT 28 38 0.75 (0.39–1.42) 848 474 1.79 (0.87–3.68)
Polio 3 Overall N = 72 N = 79 N = 123 N = 147
Seropositive 58% 68% 0.85 (0.67–1.09) 81% 87% 0.93 (0.84–1.04)
GMT 17 40 0.44 (0.28–0.70) 176 177 1.00 (0.70–1.42)
Boys N = 41 N = 40 N = 69 N = 79
Seropositive 56% 60% 0.93 (0.64–1.36) 80% 86% 0.93 (0.80–1.07)
GMT 20 63 0.32 (0.17–0.61) 204 192 1.07 (0.66–1.71)
Girls N = 31 N = 39 N = 54 N = 68
Seropositive 61% 77% 0.80 (0.57–1.11) 83% 88% 0.94 (0.81–1.09)
GMT 15 27 0.57 (0.30–1.05) 148 161 0.92 (0.55–1.54)
Note: Signiﬁcant results in bold. Tests for interaction between OPV0 and sex regarding the GMT ratio: 6-week-old children: p = 0.10 for polio 1, p = 0.21 for polio 3; 6-month-
old children: p = 0.55 for polio 1, p = 0.68 for polio 3.
Table 1
Baseline characteristics for 6 week-old and 6-month-old children.
6 weeks 6 months
No OPV0 N = 89 OPV0 N = 100 No OPV0 N = 124 OPV0 N = 151
Sex (boys), n (%) 50 (56) 53 (53) 70 (56) 81 (54)
Enrolled in rainy season, n (%) 85 (96) 80 (80) 61 (49) 62 (41)
Age at enrolment, days (IQR) 2 (1–5) 3 (1–5) 1 (1–4) 1 (1–4)
Anthropometric measures at enrollment into main trial
Mean length in cm (SD) 49 (2) 50 (2) 49 (2) 49 (2)
Head circumference, cm (SD) 34 (2) 34 (1) 34 (2) 34 (1)
MUAC, mm (SD) 99 (7) 99 (7) 97 (7) 96 (7)
Weight, kg (SD) 3.2 (0.4) 3.2 (0.4) 3.2 (0.4) 3.1 (0.4)
Vaccination status at 6 months of age
OPV3, n (%) – – 93 (75) 116 (77)
Pentavalent3, n (%) 79 (64) 104 (69)
Campaign mOPVt1, n (%)a – – 45 (36) 38 (25)
Maternal factors N = 89 N = 100 N = 124 N = 151
Age in years (SD) 25 (6) 24 (5) 26 (5) 26 (6)
BCG scar, n (%) 58 (65) 77 (77) 88 (72) 107 (71)
Tetanus vaccinated during pregnancy, n (%) 74 (83) 76 (76) 107 (86) 130 (86)
Total number of births (SD) 2.6 (1.7) 2.6 (1.7) 2.9 (1.9) 2.7 (1.8)
Gave birth at home, n (%)b 18 (21) 27 (29) 20 (17) 25 (17)
Mother attended school, n (%)b 66 (86) 67 (78) 94 (83) 116 (85)
Mothers, antibody levels, Polio 1 N = 89 N = 97 N = 81 + 38c N = 103 + 44c
Seropositive 98% 97% 98% 98%
GMT 77 87 77 91
Mothers, antibody levels, Polio 3 N = 85 N = 92 N = 77 + 36c N = 99 + 41c
Seropositive 96% 92% 97% 94%
GMT 30 41 33 38
Signiﬁcant differences in bold.
IQR: inter quartile range; GMT: geometrical mean titer.
a A subgroup of children included in the trial received mOPVt1 during a polio campaign in March 2010.
b Percentages were calculated from non-missing values.
c The child was visited at both 6 weeks and 6 months. The mother was only bled at 6 weeks, not again at 6 months.
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(0.19–0.74) for polio 3). Among children with maternal antibody
levels above the median, the difference between No OPV0 and
OPV0 was smaller and not signiﬁcant. At 6 months, the polio 1
GMT was signiﬁcantly higher in the No OPV0 group compared with
the OPV0 group among children with maternal antibody levels
above the median (GMT ratio = 2.30 (1.20–4.43). Among children
with maternal antibody levels below the median, no difference
was seen. Notably, the polio 1 GMT was highest in No OPV0 chil-
dren with maternal antibody levels below the median, and lowest
in OPV0 children with maternal antibody levels above the median.Generally, the above results were not substantially changed by
adjustment (supplementary Table 1–3).
Discussion
Main observations
Receiving OPV0 did not signiﬁcantly affect the proportion of
children with seropositive antibody levels for polio 1 and 3 at
6 weeks or 6 months of age. Not receiving OPV0 was associated
with signiﬁcantly lower antibody titers for polio 1 and 3 at 6 weeks
Table 3
Comparison of polio neutralizing antibody titers at 6 months of age in the two
randomization groups in the children who had received all polio vaccinations
according to the recommendations (OPV1–3 but not OPV in campaigns).
6 months
No OPV0 OPV0 Seropositivity ratio GMT ratio
Polio 1 Overall N = 64 N = 84
Seropositive 91% 95% 0.95 (0.87–1.04)
GMT 623 229 2.13 (1.17–3.91)
Boys N = 34 N = 48
Seropositive 97% 98% 0.99 (0.92–1.07)
GMT 766 301 2.54 (1.15–5.63)
Girls N = 30 N = 36
Seropositive 83% 92% 0.91 (0.75–1.10)
GMT 473 278 1.70 (0.68–4.26)
Polio 3 Overall N = 64 N = 81
Seropositive 78% 89% 0.88 (0.76–1.02)
GMT 143 201 0.72 (0.44–1.18)
Boys N = 34 N = 46
Seropositive 74% 87% 0.85 (0.67–1.07)
GMT 178 203 0.88 (0.44–1.74)
Girls N = 30 N = 35
Seropositive 83% 91% 0.91 (0.75–1.10)
GMT 117 197 0.59 (0.29–1.21)
Note: Signiﬁcant results in bold. Tests for interaction between OPV0 and sex
regarding the GMT ratio: p = 0.52 for polio 1, p = 0.43 for polio 3.
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body level. In contrast, at 6 months of age, children not receiving
OPV0 had signiﬁcantly higher titers of polio 1 neutralizing antibod-
ies, this was most pronounced among children of mothers with
high antibody levels.
Strengths and weaknesses
The present study was a randomized controlled trial. It is one of
the largest studies examining the antibody response to OPV0 and it
is the ﬁrst study to investigate potential sex-differential responses
to OPV0. There is obviously a risk of selection bias in a study which
only includes some children from a randomized trial. It should be
noted, though, that a lot of the loss-to-follow-up occurred for logis-
tic reasons. The group which took part in the 6-month-examina-
tion appeared to be better off than those who did not, probably
because the latter group was more often away on seasonal jobs
in the rural areas. Among the children who took part in the
antibody study, there were some differences between the random-
ization groups in girls. We have no explanation for these differ-
ences which were probably due to chance. Adjustment for these
differences did not change the results. The signiﬁcant difference
in GMT between the three persons who conducted the assaysTable 4
Comparison of polio neutralizing antibody titers at 6 weeks and 6 months of age in the two
median.
Mother’s antibody level 6 weeks
No OPV0 OPV0 Seropositivity
Polio 1 Below median N = 47 N = 44
Seropositive 74% 82% 0.91 (0.73–1.1
GMT 18 56 0.32 (0.17–0.5
Above median N = 38 N = 42
Seropositive 95% 93% 1.02 (0.91–1.1
GMT 50 64 0.78 (0.43–1.4
Polio 3 Below median N = 46 N = 38
Seropositive 48% 63% 0.76 (0.51–1.1
GMT 14 36 0.38 (0.19–0.7
Above median N = 23 N = 34
Seropositive 78% 76% 1.02 (0.77–1.3
GMT 23 34 0.68 (0.36–1.2
Note: Signiﬁcant results in bold. Tests for interaction between OPV0 and being above/
p = 0.21 for polio 3, 6-month-old children: p = 0.44 for polio 1, p = 0.62 for polio 3.was partly explained by co-variation in season and adjustment
did not change the results. It should be noted that different labora-
tories may get up to tenfold differences in titers when analyzing
the same sample [14]. As very few studies include an international
standard for reference, direct comparisons of GMT between studies
should therefore be interpreted with caution.
Only 76% of the included children had received OPV3 by the age
of 6 months and 30% received monovalent OPV against polio type 1
during the immunization campaign. Therefore, this study cannot
be directly compared to studies conducted in a more controlled set-
ting. This study does, however, reﬂect reality in most Sub-Saharan
African settings. The ofﬁcial WHO-UNICEF estimates for OPV3
coverage in Guinea-Bissau in 2009 and 2010 were 73% [15].
The national OPV campaigns diminished our sample size in the
6-week-cohort, but this cohort was otherwise not affected by the
campaigns since blood sampling was stopped before the ﬁrst cam-
paign. In the 6-month-cohort, 83 children received cOPV before
blood sampling. Furthermore, three children had not received
cOPV but were bled after the ﬁrst campaign. Exposure to cOPV,
directly or indirectly through contact with a vaccine recipient
could have increased polio 1 GMT in both randomization groups
and this would be expected to diminish any difference between
the groups. However, the results were the same in the overall
6-month-cohort and in the subgroup which had not been exposed
to cOPV.
Though this is one of the largest studies of its kind, our power to
conduct subgroup analyses was limited. Hence, the analyses
stratiﬁed by sex and by mothers antibody levels, though providing
signiﬁcant results, should be interpreted with caution.Consistency with previous studies
We found a lower proportion of seropositive 6-month-old chil-
dren than found in the early studies testing an OPV0 plus OPV1–3
schedule for OPV in which seropositivity was close to 100%
[3,16,17] for both polio 1 and polio 3 antibodies. One explanation
could be thatwehave a startingdilution of 1:8 for our assaywhereas
other studies have started at 1:5 or lower. We chose the starting
dilution of 1:8 since it is considered a protective titre. In addition
we only hadminute volumes of serum, thuswe had to start atwork-
able dilution. Last, if one uses too low dilution the speciﬁcity of the
test may diminish due to non-speciﬁc killing factors in the serum.
Nonetheless it is possible that we underestimated the proportion
of children with detectable antibodies. Only 76% of infants in our
study actually received OPV3 before the age of 6 months. However,
analyzing only the data for children who had received OPV3 (but no
cOPV) did not signiﬁcantly change the seropositivity rates. A recentrandomization groups according to mothers, antibody titers being below or above the
6 months
ratio GMT ratio No OPV0 OPV0 Seropositivity ratio GMT ratio
N = 64 N = 66
3) 86% 95% 0.90 (0.80–1.01)
9) 935 587 1.59 (0.82–3.10)
N = 54 N = 79
4) 91% 94% 0.97 (0.87–1.07)
1) 720 313 2.30 (1.20–4.43)
N = 69 N = 77
2) 80% 86% 0.92 (0.81–1.05)
4) 152 161 0.94 (0.59–1.49)
N = 43 N = 59
6) 86% 86% 1.00 (0.85–1.17)
8) 216 191 1.13 (0.64–1.99)
below median regarding the GMT ratio: 6-week-old children: p = 0.04 for polio 1,
38 A.S. Hansen et al. / Trials in Vaccinology 3 (2014) 33–39review found that after a 3-dose schedule for OPV in low-income
countries, the median seroconversion rates were 70% (range 6–
99%) and 71% (range 69–100%) for olio1 and polio 3 respectively.
After a 4-dose schedule with the ﬁrst OPV given within 7 days they
were 90% (84–100%) and 85% (63–100%) [18]. Our rates were higher
than this in both randomization groups.
More children were seropositive for polio 1 antibodies than for
polio 3 antibodies. An explanation could be that 30% of the
6-month-cohort received the monovalent OPV vaccine against
polio type 1. However, the same difference was seen in the
subgroup of children who did not receive that vaccine. A study
from The Gambia and Brazil has showed that factors which may
inﬂuence the response to OPV have their most adverse effect on
the response to polio 3 [19]. This could explain the difference in
polio 1 and polio 3 antibody responses.
Interpretation and implications
We previously found strong interactions between OPV0 and sex
with regard to mortality [6]. In the present study, though there was
no signiﬁcant interaction between OPV0 and sex, the effect of
OPV0 was signiﬁcant in its own right in boys but not in girls. Pos-
sible explanations include differences in sex hormone levels and
the fact that many immune response genes are X-linked [20].
At 6 months of age there was no difference in seropositivity be-
tween the two randomization groups. This is in line with previous
studies which have also shown that OPV0 plus OPV1–3 schedules
do not provide higher immunity at 6 months than OPV1–3
schedules [2]. However, the titers for polio 1 were signiﬁcantly
higher in children who did not receive OPV0. A similar ﬁnding
has been described for measles vaccination where early vaccina-
tion at 4 months of age was associated with a lower level of
antibodies, also after a second boost with measles vaccination at
9 months of age, than receiving one dose of measles vaccine at
9 months [21]. The common underlying explanation is probably
interference with maternal antibodies. It is well known that vacci-
nation in the presence of maternal antibodies may lead to a damp-
ened antibody response [22]. An explanation for why we only see
this for polio 1 antibodies could be that the mothers’ polio 1 titers
were higher than their polio 3 titers. Importantly, this does not
necessarily interfere with efﬁcient immunological priming [22].
There have been no reported polio cases in Guinea-Bissau for
over 10 years, but the last reported clinical cases in a neighboring
country was in 2011 [21]. With recurrent outbreaks in the region it
is important to keep the OPV coverage high. Not providing OPV at
birth could result in missed opportunities, leading to lower cover-
age. Our study was set in an urban setting, and it is expected that in
a rural setting missed vaccines could pose a bigger problem [23].
The results regarding the mortality and morbidity effects of
OPV0 will be published separately and will add information as to
the importance of keeping the policy of providing OPV0 at birth.Conclusion
OPV0 contributes to early polio protection, but not to overall
polio immunity after subsequent doses of OPV are given. At
6 months, the GMT for polio 1 was actually signiﬁcantly higher
in the No OPV0 group, presumably due to interference frommater-
nal antibodies. However, the proportion of children with seropro-
tective levels was the same.Contributions
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